Fujimoto S, Furue H, Kimura T, Kondo T, Orita K, Taguchi T, Yoshida K, Ogawa N
First Department of Surgery, School of Medicine, Chiba University, Japan.
Eur J Cancer. 1991;27(9):1114-8. doi: 10.1016/0277-5379(91)90306-x.
Adjuvant immunochemotherapy using the antitumour polysaccharide sizofiran (SPG), an extract from the culture broth of Schizophyllum commune Fries, was prescribed randomly for 386 Japanese patients with resectable gastric cancer. Although the overall survival probability for 5 years did not differ between the SPG and control groups, in 264 patients with curatively resected cancer, the probability to 5 year survival and to recurrence in the sizofiran-administered patients was better than in the controls. In the multivariate analysis, four of six prognostic factors correlated with the prognosis of the 264 patients who underwent curative surgery, that is, nodal involvement (chi 2 = 21.426, P = less than 0.0001), age distribution (chi 2 = 9.262, P = 0.010), sizofiran administration (chi 2 = 6.507, P = 0.011), and primary tumour size (chi 2 = 9.345, P = 0.025). Thus, patients with a curatively resected gastric cancer had a better prognosis when sizofiran was prescribed in combination with antitumour drugs.
对于386例可切除胃癌的日本患者，随机采用源自裂褶菌培养液提取物的抗肿瘤多糖裂褶多糖（SPG）进行辅助免疫化疗。虽然SPG组和对照组的5年总生存概率无差异，但在264例接受根治性切除癌症的患者中，使用裂褶多糖治疗的患者5年生存及复发概率优于对照组。在多因素分析中，六个预后因素中的四个与264例接受根治性手术患者的预后相关，即淋巴结受累（χ² = 21.426，P＜0.0001）、年龄分布（χ² = 9.262，P = 0.010）、裂褶多糖给药（χ² = 6.507，P = 0.011）和原发肿瘤大小（χ² = 9.345，P = 0.025）。因此，对于根治性切除的胃癌患者，当裂褶多糖与抗肿瘤药物联合使用时预后更佳。
